Category: News

Post

Nabriva Therapeutics Reports 2018 Financial Results and Recent Corporate Highlights

– Two PDUFA dates in 2019: April 30, 2019 for CONTEPO and August 19, 2019 for Lefamulin –– Company preparing for potential commercialization of two first-in-class antibiotics, Lefamulin (IV and Oral) and CONTEPO (IV) in the United States in 2019 – DUBLIN, Ireland, March 12, 2019 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical...

Post

SCYNEXIS is Retiring Existing Term Loan Through a Lower-Interest and Longer-Term Convertible Note

JERSEY CITY, N.J., March 7, 2019 /PRNewswire/ — SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced the sale of a $16.0 million aggregate principal amount of 6.0% convertible senior note due 2025 (the “note”). The note was sold in a private offering to Puissance Capital Management pursuant...

Post

Melinta Therapeutics to Report Fourth Quarter and Year-End 2018 Financial Results on March 13, 2019

MORRISTOWN, N.J., March 05, 2019 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced it intends to release its fourth quarter and year-end 2018 financial results on March 13, 2019, after the close of the U.S. financial...

Post

ContraFect Announces $6.94 Million in Funding from CARB-X to Support Development of Amurin Platform Against All Gram-negative ESKAPE Pathogens

Newly discovered class of bacteriophage-derived lytic agents called ‘amurins’ aims to treat the deadliest drug-resistant Gram-negative pathogens YONKERS, N.Y., March 04, 2019 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that the Combating Antibiotic Resistant...

Post

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

BOSTON, March 01, 2019 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that on February 28, 2019, the Company granted stock options and restricted stock units to three new employees of the Company. These awards were granted pursuant to the...

Post

Paratek Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference

About Paratek Pharmaceuticals, Inc.Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics. The company’s lead commercial product, NUZYRA (omadacycline), which has launched and is available in the U.S., is a once-daily intravenous and oral antibiotic for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin...

Post

SCYNEXIS to Present Pre-clinical Data Supporting Prophylactic Use of Ibrexafungerp at Superbugs and Superdrugs 2019

JERSEY CITY, N.J., Feb. 28, 2019 /PRNewswire/ — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present new in vivo data supporting the potential use of oral ibrexafungerp (formerly SCY-078) for the prevention and treatment of Pneumocystis pneumonia (PCP), a significant risk for immunocompromised...

February 28, 2019February 28, 2019by In News
Post

Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

 — NUZYRA™ (omadacycline) Launched in the United States for the Treatment of CABP and ABSSSI — — New England Journal of Medicine Publishes Results from Two Pivotal Phase 3 Studies of NUZYRA — — Company Executes SEYSARA™ Royalty-Backed Loan to Receive $32.5 Million — BOSTON, Feb. 27, 2019 (GLOBE NEWSWIRE) — Paratek...

February 27, 2019February 27, 2019by In News
Post

Melinta Therapeutics Announces Closing of Initial $75 Million Vatera Convertible Loan Funding

– Amendment to Deerfield Facility Agreement Becomes Effective – – John H. Johnson Appointed Permanent Chief Executive Officer – – Company to Report Fourth Quarter and Full Year 2018 Financial Results on March 13, 2019 – MORRISTOWN, N.J., Feb. 25, 2019 (GLOBE NEWSWIRE) —  Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the...

February 25, 2019February 25, 2019by In News
Post

Summit’s SMT-571 Potent Against Over 200 Clinical Isolates of Neisseria Gonorrhoeae, Including Numerous Multi- and Extensively-Drug Resistant Strains, in Published Preclinical Data

Summit Therapeutics plc  (‘Summit’ or the ’Company’) Summit’s SMT-571 Potent Against Over 200 Clinical Isolates of Neisseria Gonorrhoeae, Including Numerous Multi- and Extensively-Drug Resistant Strains, in Published Preclinical Data Data Highlight SMT-571’s Potential to Address Global Gonorrhoea Threat Oxford, UK, and Cambridge, MA, US, 25 February 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM),...

February 25, 2019February 25, 2019by In News